Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | PMM2 | O15305 | 2/20 | 0.32 |
| ▸ | MPI | P34949 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58545 | 0.85 | CYP3A4 (0.60) | CYP3A4GABRA1GABRB2TDP1MAPK1 | |
| SCHEMBL93182 | 0.79 | CYP3A4 (0.54) | CYP3A4GABRA1GABRB2TDP1MAPK1 | |
| SCHEMBL29862583 | 0.79 | CYP3A4 (0.54) | CYP3A4GABRA1GABRB2TDP1MAPK1 | |
| SCHEMBL93220 | 0.79 | CYP3A4 (0.52) | CYP3A4GABRA1GABRB2TDP1MAPK1 | |
| SCHEMBL29463737 | 0.79 | CYP3A4 (0.52) | CYP3A4GABRA1GABRB2TDP1MAPK1 | |
| SCHEMBL2169198 | 0.78 | CYP3A4 (0.52) | CYP3A4GABRA1GABRB2TDP1TRPA1 | |
| Ammonia Solution, Strong SCHEMBL28180433 | 0.78 | CYP3A4 (0.52) | CYP3A4GABRA1GABRB2TDP1MAPK1 | |
| SCHEMBL2291859 | 0.76 | CYP3A4 (0.60) | CYP3A4GABRA1GABRB2TDP1MAPK1 | |
| SCHEMBL15351819 | 0.76 | CYP3A4 (0.73) | CYP3A4GABRA1GABRB2TDP1TRPA1 | |
| SCHEMBL1901940 | 0.76 | CYP3A4 (0.50) | CYP3A4GABRA1GABRB2TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768764-A | Process for preparing urea derivatives | 安道麦阿甘有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-116768764-A | Process for preparing urea derivatives | 安道麦阿甘有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-108753220-A | A kind of high temperature resistant, solvent-proof phenolic resin film | 长春峰泰汽车胶业有限公司 | 2018-11-06 | — | — | CN | disclosed |
| CN-104418866-B | Dgat1 inhibitor and its preparation method and application | 青岛黄海制药有限责任公司 | 2018-10-16 | — | — | CN | disclosed |
| US-20120219885-A1 | NOVEL NON-CRYSTALLIZING METHACRYLATES, PRODUCTION AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219885-A1 | NOVEL NON-CRYSTALLIZING METHACRYLATES, PRODUCTION AND USE THEREOF | MEP1A, MMAB, RHOA | CYP3A4 2674/4885GABRA1 3955/4885GABRB2 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.